Clinical trial · Observational
The Treatment Situation of Chinese County Population With Breast Cancer
A Multi-center, Observational Study to Describe the Treatment Situation of Chinese County Population With HER2+ & HR+/HER2- Breast Cancer
NCT05544123CI-TRIAL-00062997unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is a multi-center, non-interventional, prospective observational study which enrols 2500 breast cancer patients from China county area. The purpose of this study is to be aware of the real-world data of the current breast cancer diagnosis and treatment model in the county. It aims to understand the gap between the county and the SOC in the diagnosis and treatment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Breast Carcinoma | Breast Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Breast Tumor | Breast Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pathological stage | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Cohort 1 HER2+ EBC
- description
- newly diagnosed or completed definitive breast surgery
- interventionNames
- Other: pathological stage
- label
- Cohort 2 HR+ HER2- EBC
- description
- newly diagnosed or completed definitive breast surgery
- interventionNames
- Other: pathological stage
- label
- Cohort 3 HER2+ ABC
- description
- De novo or relapsed from adjuvant therapy
- interventionNames
- Other: pathological stage
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Cohort 1 * Age ≥ 18 years at the time of enrollment * Histologically confirmed HER2+ breast cancer * Newly diagnosed or completed definitive early breast surgery * Complete medical history information Cohort 2 * Age ≥ 18 years at the time of enrollment * Histologically confirmed HR+ HER2- breast cancer * Newly diagnosed or completed definitive early breast surgery * Complete medical history information Cohort 3 * Age ≥ 18 years at the time of enrollment * Histologically confirmed HER2+ breast cancer * De Novo or recurrent metastatic breast cancer * Complete medical history information Cohort 4 * Age ≥ 18 years at the time of enrollment * Histologically confirmed HR+ HER2- breast cancer * De Novo or recurrent metastatic breast cancer * Complete medical history information Exclusion Criteria: Cohort 1 * Participated in other Intervention drug clinical trials within 4 weeks before admission Cohort 2 * Participated in other Intervention drug clinical trials within 4 weeks before admission Cohort 3 * Patients with HER2 + advanced breast cancer who have received more than 2 lines of therapy * Participated in other Intervention drug clinical trials within 4 weeks before admission Cohort 4 * Patients with HR+ HER2- advanced breast cancer who have received more than 2 lines of therapy * Participated in other Intervention drug clinical trials within 4 weeks before admission
References
Publications (0)
Data not yet available
No reference posted for this study.